RESULTS	Overall , treatment with alendronate was associated with a 48 percent reduction in the proportion of women with new vertebral fractures ( 3.2 percent , vs. 6.2 percent in the placebo group ; P = 0.03 ) , a decreased progression of vertebral deformities ( 33 percent , vs. 41 percent in the placebo group ; P = 0.028 ) , and a reduced loss of height ( P = 0.005 ) and was well tolerated .\